154 related articles for article (PubMed ID: 12406847)
1. Interstitial vascularity in fibrosing alveolitis.
Renzoni EA; Walsh DA; Salmon M; Wells AU; Sestini P; Nicholson AG; Veeraraghavan S; Bishop AE; Romanska HM; Pantelidis P; Black CM; Du Bois RM
Am J Respir Crit Care Med; 2003 Feb; 167(3):438-43. PubMed ID: 12406847
[TBL] [Abstract][Full Text] [Related]
2. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis.
Wells AU; Cullinan P; Hansell DM; Rubens MB; Black CM; Newman-Taylor AJ; Du Bois RM
Am J Respir Crit Care Med; 1994 Jun; 149(6):1583-90. PubMed ID: 8004317
[TBL] [Abstract][Full Text] [Related]
3. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison.
Wells AU; Hansell DM; Rubens MB; Cailes JB; Black CM; du Bois RM
Am J Respir Crit Care Med; 1997 May; 155(5):1657-64. PubMed ID: 9154872
[TBL] [Abstract][Full Text] [Related]
4. Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis.
Wells AU; Hansell DM; Haslam PL; Rubens MB; Cailes J; Black CM; du Bois RM
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1474-82. PubMed ID: 9603126
[TBL] [Abstract][Full Text] [Related]
5. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies.
Majumdar S; Li D; Ansari T; Pantelidis P; Black CM; Gizycki M; du Bois RM; Jeffery PK
Eur Respir J; 1999 Aug; 14(2):251-7. PubMed ID: 10515397
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-8. Differential expression in lone fibrosing alveolitis and systemic sclerosis.
Southcott AM; Jones KP; Li D; Majumdar S; Cambrey AD; Pantelidis P; Black CM; Laurent GJ; Davies BH; Jeffery PK
Am J Respir Crit Care Med; 1995 May; 151(5):1604-12. PubMed ID: 7735620
[TBL] [Abstract][Full Text] [Related]
7. Cryptogenic fibrosing alveolitis and the fibrosing alveolitis of systemic sclerosis: morphological differences on computed tomographic scans.
Chan TY; Hansell DM; Rubens MB; du Bois RM; Wells AU
Thorax; 1997 Mar; 52(3):265-70. PubMed ID: 9093344
[TBL] [Abstract][Full Text] [Related]
8. Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium.
Wells AU; Lorimer S; Majumdar S; Harrison NK; Corrin B; Black CM; Jeffery PK; du Bois RM
Eur Respir J; 1995 Feb; 8(2):266-71. PubMed ID: 7758562
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil activation in fibrosing alveolitis: a comparison of lone cryptogenic fibrosing alveolitis and systemic sclerosis.
Cailes JB; O'Connor C; Pantelidis P; Southcott AM; Fitzgerald MX; Black CM; du Bois RM
Eur Respir J; 1996 May; 9(5):992-9. PubMed ID: 8793462
[TBL] [Abstract][Full Text] [Related]
10. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis.
Renzoni E; Lympany P; Sestini P; Pantelidis P; Wells A; Black C; Welsh K; Bunn C; Knight C; Foley P; du Bois RM
Arthritis Rheum; 2000 Jul; 43(7):1633-40. PubMed ID: 10902769
[TBL] [Abstract][Full Text] [Related]
11. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis.
Avila JJ; Lympany PA; Pantelidis P; Welsh KI; Black CM; du Bois RM
Am J Respir Cell Mol Biol; 1999 Jan; 20(1):106-12. PubMed ID: 9870923
[TBL] [Abstract][Full Text] [Related]
12. T-cell receptor gene usage in patients with fibrosing alveolitis and control subjects.
Lympany PA; Southcott AM; Welsh KI; Black CM; Boylston AW; du Bois RM
Eur J Clin Invest; 1999 Feb; 29(2):173-81. PubMed ID: 10093005
[TBL] [Abstract][Full Text] [Related]
13. Structural features of interstitial lung disease in systemic sclerosis.
Harrison NK; Myers AR; Corrin B; Soosay G; Dewar A; Black CM; Du Bois RM; Turner-Warwick M
Am Rev Respir Dis; 1991 Sep; 144(3 Pt 1):706-13. PubMed ID: 1892314
[TBL] [Abstract][Full Text] [Related]
14. Exhaled nitric oxide is increased in active fibrosing alveolitis.
Paredi P; Kharitonov SA; Loukides S; Pantelidis P; du Bois RM; Barnes PJ
Chest; 1999 May; 115(5):1352-6. PubMed ID: 10334152
[TBL] [Abstract][Full Text] [Related]
15. Tenascin immunoreactivity in cryptogenic fibrosing alveolitis.
Wallace WA; Howie SE; Lamb D; Salter DM
J Pathol; 1995 Apr; 175(4):415-20. PubMed ID: 7540684
[TBL] [Abstract][Full Text] [Related]
16. Evidence of increased histamine levels of lung lavage fluids from patients with cryptogenic fibrosing alveolitis.
Haslam PL; Cromwell O; Dewar A; Turner-Warwick M
Clin Exp Immunol; 1981 Jun; 44(3):587-93. PubMed ID: 7326869
[TBL] [Abstract][Full Text] [Related]
17. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography.
Wells AU; Hansell DM; Rubens MB; King AD; Cramer D; Black CM; du Bois RM
Arthritis Rheum; 1997 Jul; 40(7):1229-36. PubMed ID: 9214422
[TBL] [Abstract][Full Text] [Related]
18. Immunoreactive interleukin 4 and interferon-gamma expression by type II alveolar epithelial cells in interstitial lung disease.
Wallace WA; Howie SE
J Pathol; 1999 Mar; 187(4):475-80. PubMed ID: 10398109
[TBL] [Abstract][Full Text] [Related]
19. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.
Bouros D; Wells AU; Nicholson AG; Colby TV; Polychronopoulos V; Pantelidis P; Haslam PL; Vassilakis DA; Black CM; du Bois RM
Am J Respir Crit Care Med; 2002 Jun; 165(12):1581-6. PubMed ID: 12070056
[TBL] [Abstract][Full Text] [Related]
20. Terminal diffuse alveolar damage in relation to interstitial pneumonias. An autopsy study.
Rice AJ; Wells AU; Bouros D; du Bois RM; Hansell DM; Polychronopoulos V; Vassilakis D; Kerr JR; Evans TW; Nicholson AG
Am J Clin Pathol; 2003 May; 119(5):709-14. PubMed ID: 12760290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
